221 related articles for article (PubMed ID: 5729592)
1. Ocular toxicity of antimalarial drugs. Long-term follow-up.
Carr RE; Henkind P; Rothfield N; Siegel IM
Am J Ophthalmol; 1968 Oct; 66(4):738-44. PubMed ID: 5729592
[No Abstract] [Full Text] [Related]
2. Ocular damage in chloroquine therapy.
Nylander U
Acta Ophthalmol (Copenh); 1967; ():Suppl 92:1-71. PubMed ID: 4866642
[No Abstract] [Full Text] [Related]
3. [Supervision of the eyes during prolonged treatment with synthetic antimalarial drugs. Results in 237 patients followed up for 4 years on the average].
Bertrand JJ; Debeyre N; Kahn MF; Ryckewaert A
Presse Med (1893); 1968 Nov; 76(45):2139-42. PubMed ID: 5720115
[No Abstract] [Full Text] [Related]
4. [Eye toxicity of antimalarial agents].
Graña Gil J; Cabana Vázquez M; Vázquez González A; Sánchez Meizoso MO
An Med Interna; 2002 Apr; 19(4):189-91. PubMed ID: 12090061
[TBL] [Abstract][Full Text] [Related]
5. Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity?
McCune WJ; Gonzalez-Rivera T
Curr Opin Rheumatol; 2015 May; 27(3):213-5. PubMed ID: 25784384
[No Abstract] [Full Text] [Related]
6. Ocular effects and safety of antimalarial agents.
Easterbrook M
Am J Med; 1988 Oct; 85(4A):23-9. PubMed ID: 3177429
[TBL] [Abstract][Full Text] [Related]
7. [Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses].
Rüther K; Foerster J; Berndt S; Schroeter J
Ophthalmologe; 2007 Oct; 104(10):875-9. PubMed ID: 17653725
[TBL] [Abstract][Full Text] [Related]
8. [Antimalarial's retinopaty remains a current threat].
Chiffoleau A; Guillet A; Zanlonghi X; Jolliet P
Presse Med; 2009 Apr; 38(4):662-3. PubMed ID: 19135848
[No Abstract] [Full Text] [Related]
9. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine.
Laaksonen AL; Koskiahde V; Juva K
Scand J Rheumatol; 1974; 3(2):103-8. PubMed ID: 4608161
[No Abstract] [Full Text] [Related]
10. Long-term course of chloroquine retinopathy after cessation of medication.
Brinkley JR; Dubois EL; Ryan SJ
Am J Ophthalmol; 1979 Jul; 88(1):1-11. PubMed ID: 463998
[TBL] [Abstract][Full Text] [Related]
11. Antimalarials in the management of discoid and systemic lupus erythematosus.
Dubois EL
Semin Arthritis Rheum; 1978 Aug; 8(1):33-51. PubMed ID: 358397
[No Abstract] [Full Text] [Related]
12. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus.
Jiménez-Alonso J; Tercedor J; Jáimez L; García-Lora E
Arthritis Rheum; 1998 Apr; 41(4):744-5. PubMed ID: 9550488
[No Abstract] [Full Text] [Related]
13. Electroretinography in patients with connective tissue diseases treated with hydroxychloroquine.
Sassaman FW; Cassidy JT; Alpern M; Maaseidvaag F
Am J Ophthalmol; 1970 Oct; 70(4):515-23. PubMed ID: 5505469
[No Abstract] [Full Text] [Related]
14. [Combination of antimalarial drugs mepacrine and chloroquine in therapy refractory cutaneous lupus erythematosus].
von Schmiedeberg S; Rönnau AC; Schuppe HC; Specker C; Ruzicka T; Lehmann P
Hautarzt; 2000 Feb; 51(2):82-5. PubMed ID: 10743578
[TBL] [Abstract][Full Text] [Related]
15. Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know.
Teboul A; Arnaud L; Chasset F
J Dermatol; 2024 Jul; 51(7):895-903. PubMed ID: 38482997
[TBL] [Abstract][Full Text] [Related]
16. Chloroquine: ophthalmological safety, and clinical assessment in rheumatoid arthritis.
Percival SP; Meanock I
Br Med J; 1968 Sep; 3(5618):579-84. PubMed ID: 4875645
[TBL] [Abstract][Full Text] [Related]
17. [Routine monitoring of patients treated with synthetic antimalarials].
Douche C; Bechetoille A; Ebran JM
J Fr Ophtalmol; 1983; 6(8-9):689-95. PubMed ID: 6677659
[TBL] [Abstract][Full Text] [Related]
18. Complications of antimalarial therapy.
Lozier JR; Friedlaender MH
Int Ophthalmol Clin; 1989; 29(3):172-8. PubMed ID: 2666332
[No Abstract] [Full Text] [Related]
19. Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus.
Chacón-Dulcey V; López-Labady J; Villarroel-Dorrego M; Frías J; Tirado W; González N; Pérez Alfonzo R
Lupus; 2020 Jun; 29(7):761-766. PubMed ID: 32362181
[TBL] [Abstract][Full Text] [Related]
20. [Antimalarial drug retinopathy].
Guiot A; Couturier M; Tebib JG; Abouaf L; Coury F
Rev Med Interne; 2018 May; 39(5):364-368. PubMed ID: 29496271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
